Phaseline

Companies › CellCentric

CellCentric: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 1 Phase 2, 1 Phase 1, 1 Phase 3; Oncology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Pomalidomide (CCS1477)
CRL4(CRBN) E3 ubiquitin ligase inhibitor
CRBN, DDB1, CUL4A, RBX1Phase 3Multiple Myeloma RefractoryNov 2029
CCS1477 (Inobrodib)–Phase 2Multiple Myeloma Refractory; Haematological MalignancyMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04068597CCS1477 (Inobrodib)Phase 1Haematological MalignancyOncologyMar 2027
NCT07772024Pomalidomide (CCS1477)Phase 3Multiple Myeloma RefractoryOncologyNov 2029
NCT07096778CCS1477 (Inobrodib)Phase 2Multiple Myeloma RefractoryOncologyDec 2029

Targets

CRBN (1) DDB1 (1) CUL4A (1) RBX1 (1)

Companies with the same targets

Bristol-Myers Squibb Roche Incyte Shandong New Time Pharmaceutical Beijing InnoCare Pharma Tech

Companies built like this

IO Biotech iOnctura Toray Industries SynerGene Therapeutics Lyvgen Biopharma Holdings

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.